Zacks Investment Research upgraded shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) from a hold rating to a buy rating in a research report report published on Friday. Zacks Investment Research currently has $1.75 target price on the biopharmaceutical company’s stock.
According to Zacks, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. “
Marinus Pharmaceuticals (NASDAQ:MRNS) traded down 1.91% on Friday, hitting $1.54. 685,728 shares of the company were exchanged. The stock’s market capitalization is $30.35 million. The stock’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.32. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $6.76.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Monday, March 13th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post ($1.05) earnings per share for the current fiscal year.
Your IP Address:
An institutional investor recently bought a new position in Marinus Pharmaceuticals stock. Susquehanna International Group LLP acquired a new stake in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 57,767 shares of the biopharmaceutical company’s stock, valued at approximately $105,000. Susquehanna International Group LLP owned about 0.30% of Marinus Pharmaceuticals as of its most recent filing with the SEC. 30.88% of the stock is owned by institutional investors and hedge funds.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.